Market Overview
| Study Period | 2020 - 2031 |
|---|---|
| Forecast Data Period | 2026 - 2031 |
| Historical Data Period | 2020 - 2024 |
| Growth Rate | 11.27% CAGR |
| Market Concentration | Medium |
Major Players *Disclaimer: Major Players sorted in no particular order Image © Â鶹ÊÓƵ. Reuse requires attribution under CC BY 4.0. | |
Asia-Pacific Continuous Glucose Monitoring Market Analysis by Â鶹ÊÓƵ
The Asia-Pacific Continuous Glucose Monitoring Market size is expected to register a CAGR of 11.27% during the forecast period (2026-2031).
The COVID-19 pandemic positively impacted the Asia-Pacific Diabetes Care Devices Market growth. Patients with diabetes, infected with COVID-19 may experience elevated blood glucose, abnormal glucose variability, and diabetic complications. The prevalence of diabetes in people with COVID-19 caused a significant increase in severity and mortality of COVID-19 in people with either type 1 (T1DM) or type 2 diabetes mellitus (T2DM), especially in association with poor glycemic control. While new-onset hyperglycemia and new-onset diabetes (both T1DM and T2DM) have been increasingly recognized in the context of COVID-19 and have been associated with worse outcomes. To avoid aggravation, a patient's blood glucose should be monitored regularly, which has underlined the importance of blood glucose monitoring devices. The pandemic emergency has created a rise in remote care from both patients and providers and removed many long-standing regulatory barriers.
According to International Diabetes Federation (IDF), 90 million adults (20-79) are living with diabetes in the IDF South-East Asia (SEA) Region in 2021. This figure is estimated to increase to 152 million by 2045 and 206 million adults (20-79) are living with diabetes in the IDF Western Pacific Region in 2021 which is estimated to increase to 260 million by 2045. The main diagnosis for diabetes patients is imbalances in blood glucose levels, which are not in compliance with the standard blood glucose levels. The general lab diagnostic tests can only help to diagnose the disease by physicians. Patients with more fluctuations in glucose levels need to get it checked every day. Patients administering insulin need to check their blood glucose levels frequently, adjust the doses of insulin, or change the medication, if necessary.
The incidence of newly diagnosed cases of Type 1 and Type 2 diabetes is observed to be on the rise, primarily attributed to factors such as obesity, unhealthy dietary habits, and lack of physical activity. The escalating frequency and pervasiveness of diabetic patients and healthcare expenses in developed nations are indicative of the growing utilization of diabetic care products. Furthermore, the mounting adoption of insulin delivery devices and the surging prevalence of diabetes are propelling the expansion of the market. Prominent manufacturers are directing their efforts towards technological advancements and the creation of sophisticated products to secure a significant market share.
Note: Market size and forecast figures in this report are generated using Â鶹ÊÓƵ’s proprietary estimation framework, updated with the latest available data and insights as of 2026.
Asia-Pacific Continuous Glucose Monitoring Market Trends and Insights
The sensors Segment is having the highest market share in Asia-Pacific Continuous Glucose Monitoring Market.
Continuous glucose monitoring sensors use glucose oxidase to detect blood sugar levels. Glucose oxidase converts glucose to hydrogen peroxidase, which reacts with the platinum inside the sensor, producing an electrical signal to be communicated to the transmitter. Sensors are an essential part of continuous glucose monitoring devices. Technological advancements to improve the accuracy of the sensors are expected to drive segment growth during the forecast period. Continuous glucose monitoring has become a popular alternative to the portable finger-prick glucometers available in the market for the convenience of diabetic patients. According to a research study by Ziyi Yu et al., published in IOP Science Journal in March 2021, a large variety of promising glucose-sensing technologies, from traditional electrochemical-based glucose sensors to novel optical and other electrical glucose sensors, has been developed which shows a positive impact on the market growth.
Furthermore, the current continuous glucose monitoring devices can either display the trends in blood glucose levels by downloading the data or give a real-time picture of glucose levels through receiver displays. Continuous glucose monitoring devices are becoming cheaper with the advent of new technologies, like cell phone integration, which is likely to drive the segment. The market players are adopting various strategies and innovations to increase market share. For instance, In July 2021, Terumo Corporation announced the launching the Dexcom G6 continuous glucose monitoring (CGM) system in Japan. U.S.-based Dexcom manufactures the Dexcom product, and Terumo holds the exclusive distribution agreement of Dexcom Products in Japan.
Asia-Pacific region has the two highest diabetes populations in the world. With the increasing type-1 diabetes population in the area, the segment is expected to grow over the forecast period.
China is Expected to Dominate the Asia-Pacific Continuous Glucose Monitoring Devices Market.
China dominates around 56% of the Asia-Pacific Insulin Infusion Pump Market among the Asia-Pacific countries. This is mainly due to the high diabetes prevalence in this country. China records the highest healthcare expenditure in the Asia-Pacific region. According to the National Bureau of Statistics of China, MOH (China), in 2021, China's expenditure on health and hygiene was Yuan 1,920.5 billion (USD 263.32 billion). Expenditure includes government, collective, and private out-of-pocket spending on health care. Health insurance is voluntary in China, but the share of the population being covered by basic health insurance has increased in the last ten years.
China stands third in number among the countries with the highest diabetes population. Type 2 diabetes (T2D) has rapidly increased over the past decade, becoming a leading public health challenge in China. The increasing number of diabetes patients drives the growth in the Chinese diabetic market, the increase in high-calorie diets, and sedentary lifestyles. This has led the country to record the highest number of diabetes patients globally, totaling 129 million people in 2021, roughly 8.5% of the population. Â鶹ÊÓƵ 129 million people were suffering from diabetes mellitus in 2021, with a prevalence of 10% among adults. Of the 129 million diabetic patients, 12.75 million were Type 1 patients, and 116.85 million were Type 2 patients.
Therefore, owing to the factors above, the growth of the studied market is anticipated in the Asia-Pacific Region.
Competitive Landscape
A significant share of the Asia-Pacific Continuous Glucose Monitoring Devices market study is held by CGM manufacturers concurrently with strategy-based M&A operations. These manufacturers continuously enter new markets to generate new revenue streams and boost existing ones. The market studied is consolidated with Dexcom, Abbott, and Medtronic, holding a high market share, followed by regional manufacturers accounting for a relatively smaller share.
Asia-Pacific Continuous Glucose Monitoring Industry Leaders
Dexcom
Medtronic
Abbott
Senseonics
Ascensia
- *Disclaimer: Major Players sorted in no particular order
Market Opportunities and Future Outlook
Opportunities in Asia-Pacific CGM increasingly hinge on localization of supply and faster commercialization across fragmented regulatory pathways. Dexcoms Malaysia expansion is a concrete example of how manufacturers build regional operations to support scale, including the company opening its first manufacturing facility outside the United States in Batu Kawan, Penang in November 2024, and continuing site investments in April 2026 with an on-site sports complex to support longer-term operations. Alongside these manufacturing footprints, multi-analyte sensing is moving from concept to marketed platforms, highlighted by Abbott securing a CE Mark in May 2026 for dual glucose-ketone sensing (Libre Duo), which extends the product roadmap for advanced monitoring and tighter integration with insulin delivery and decision support systems.
Demand-side upside also depends on broader real-world access and interoperability across healthcare IT and consumer digital ecosystems, particularly in high-diabetes-burden markets such as China and across advanced digital health hubs including Japan, South Korea, and Australia. The market still faces region-specific evidence and approval requirements across regulators such as Chinas NMPA, Japans PMDA, and Australias TGA, so region-by-region launches and localized clinical and cybersecurity compliance can translate into share gains. Reimbursement and clinical pathway inclusion remain key adoption gates, so suppliers that invest in health-system integrations and payer-relevant outcomes have room to differentiate with sensor-led platforms that can plug into hospital and remote-care workflows.
Recent Industry Developments
- June 2026: MiniMed expanded its agreement with Abbott to collaborate on commercializing integrated dual glucose-ketone sensors designed to work with MiniMed smart dosing systems. The cooperation indicates tighter coupling of sensing with automated dosing workflows, setting a higher bar for CGM offerings aimed at broader metabolic safety monitoring beyond glucose alone.
- March 2025: Abbott enabled FreeStyle Libre 2 CGM data integration with LabConnect in South Korea via iKooBs platform, allowing glucose data to flow directly into hospital systems. This supports CGMs integration into provider workflows and helps enable enterprise adoption alongside patient-managed monitoring.
- November 2024: Dexcom opened its first manufacturing facility outside the United States in Batu Kawan, Penang, Malaysia, backed by a large investment commitment. Establishing regional production capacity supports supply resilience and positions Malaysia as a hub for serving Asia-Pacific demand and export requirements.
Research Methodology Framework and Report Scope
Market Definition and Coverage
This market covers revenues from continuous glucose monitoring (CGM) systems sold and used across Asia Pacific, including sensors and durable hardware used to capture, transmit, and display glucose readings for diabetes management.
Scope exclusions: The sizing excludes blood glucose test strips and lancets, standalone insulin delivery devices, and any services that are not directly tied to CGM device and component sales.
Segmentation Overview
- Component
- Sensors
- Durables
- Geography
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- South Korea
- Thailand
- Vietnam
- Rest of Asia-Pacific
Data Sources, Market Sizing, and Validation
Desk Research
Desk work starts by forming a clear demand context for CGM in Asia Pacific, then matching that to what is realistically available and paid for across countries. Public sources such as the World Health Organization, International Diabetes Federation, World Bank, UN Comtrade, and OECD Health Statistics (where available) are used to anchor diabetes burden, population structure, and trade directionality.
We also review manufacturer public disclosures such as annual reports, investor presentations, and product documentation to understand component mix (sensors versus durables) and typical replacement patterns. Policy and access signals are checked through regulator and health ministry updates on reimbursement and procurement, along with peer-reviewed clinical and health economics papers that reference CGM usage in practice. Select paid subscriptions are used only for company financials tracking, news screening, and patent landscaping to keep launch timing assumptions aligned to what is being announced. These sources are illustrative only, and many other public references are used for data collection, validation, and clarification.
Primary Interviews and Surveys
Primary work focuses on validating the practical inputs that move the market size most, especially price bands by channel, the sensor wear duration seen in the field, and how reimbursement is influencing uptake. Interviews cover manufacturers, distributors, clinicians, and payer or procurement stakeholders across key APAC countries, then outlier assumptions are rechecked through follow-up discussions to avoid one-sided views.
Distribution of primary research fieldwork respondents
| Company type | Respondent position | Region |
|---|---|---|
| Top tier: 26% | CXOs: 13% | |
| Mid tier: 58% | Functional/Unit leaders: 30% | |
| Smaller Players: 16% | Managers: 57% |
Market-Sizing & Forecasting
We size the market using top-down and bottom-up logic that can be repeated with limited inputs. The top-down build starts from the diabetes and treated population pool by country, then applies CGM adoption and replacement behavior to estimate annual sensor demand and the related need for receivers and transmitters.
To keep the model anchored, we use a defined set of variables, including diagnosed and treated share, insulin-using cohort size, sensor wear duration and replacement frequency, durable refresh cycles, reimbursement breadth, and expected average selling price movement under tendering and higher volumes. Totals are then checked with selective bottom-up approximations, including sampled ASPs times estimated unit volumes, plus high-level supplier and channel revenue checks that can be supported by public disclosures and interview feedback. When a country has limited visibility, gaps are filled using peer-market ratios adjusted for population mix, access, and reimbursement stage.
For forecasting, scenario analysis is applied so pricing and uptake can move differently across markets that are expanding coverage versus those that remain mostly self-pay. Scenario ranges are informed by primary expert consensus, and the chosen case is kept consistent with visible policy timelines and adoption signals.
Data Validation & Update Cycle
Outputs are compared with independent signals before sign-off, including known reimbursement changes, procurement and tender timing, and the unit movement direction implied by replacement cycles. Any large jumps are reviewed in an analyst pass, and the driver behind the change is traced back to one or two inputs so it can be explained clearly.
If conflicts remain, selected respondents are recontacted and desk inputs are revisited until the variance is resolved. Reports refresh annually, with interim updates when material events occur, such as a major policy shift, a sizable pricing reset, or a meaningful product launch. Before delivery, a final check is completed so clients receive the latest updated assumptions and calculations.
Â鶹ÊÓƵ's Asia Pacific Continuous Glucose Monitoring Market Size Compared With Other Published Estimates
Published market values for Asia Pacific CGM do not always match because the counted basket of products and the country coverage can shift from one publisher to another. Differences also show up when one model assumes faster uptake in self-care or a quicker drop in sensor pricing, even though reimbursement expansion varies widely across the region.
Import and shipment directionality, reimbursement and procurement signals by country, and sensor replacement-cycle math are the evidence points that keep Â鶹ÊÓƵ tied to sensor and durable component revenues, without folding in broader glucose monitoring supplies or unrelated digital care services. Currency timing and how ASP erosion is handled under tendering also matter, since small changes in price assumptions can move the total quickly when volumes are rising.
Benchmark comparison
| Source | Market Size | Gaps in Research Methodology |
|---|---|---|
| Â鶹ÊÓƵ | USD 0.00 B (2026) | |
| Global Consultancy A | USD 2.94 B (2024) | Uses a different base year and typically applies faster adoption and higher blended pricing across markets, which can overstate near-term value when reimbursement is still uneven by country. |
| Industry Publisher B | USD 0.49 B (2030) | Represents only Southeast Asia with a separate forecast window, so it misses higher-value markets elsewhere in APAC and changes the impact of reimbursement and pricing dynamics. |
The spread is largely explained by geography coverage and what is included around the core CGM system. When sizing is kept to sensors plus durable hardware and is then tested against replacement rates, policy signals, and realistic country price bands, the result stays traceable to inputs that can be rechecked.
Key Questions Answered in the Report
What is the current Asia-Pacific Continuous Glucose Monitoring Market size?
The Asia-Pacific Continuous Glucose Monitoring Market is projected to register a CAGR of 11.27% during the forecast period (2026-2031)
Who are the key players in Asia-Pacific Continuous Glucose Monitoring Market?
Dexcom, Medtronic, Abbott, Senseonics and Ascensia are the major companies operating in the Asia-Pacific Continuous Glucose Monitoring Market.
What years does this Asia-Pacific Continuous Glucose Monitoring Market cover?
The report covers the Asia-Pacific Continuous Glucose Monitoring Market historical market size for years: 2019, 2020, 2021, 2022, 2023, 2024 and 2025. The report also forecasts the Asia-Pacific Continuous Glucose Monitoring Market size for years: 2026, 2027, 2028, 2029, 2030 and 2031.
Page last updated on:
